ASO

EDU

HTN

PREV

GUIDELINES

Guidelines

CURRENT ISSUES IN DYSLIPIDEMIA MANAGEMENT

Co-Chair(s)

• 

  Glen Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS

  Professor of Medicine (Cardiology)
  Member
• George T.

  George Thanassoulis

  Associate Professor of Medicine, McGill University

Presenter(s)

• Arden B.

  Arden Barry

  Clinical Pharmacy and Research Specialist
• 

  Eva Lonn, MD, MSc, FRCPC, FACC

  Professor of Medicine and Population Health Research Senior Scientist, McMaster University
  McMaster University
• George T.

  George Thanassoulis

  Associate Professor of Medicine, McGill University

Dyslipidemia is one of the major modifiable risk factors for cardiovascular disease (CVD). While new evidence demonstrates betters outcomes for patients and increases our knowledge of dyslipidemia management, the ever-changing landscape of lipid treatment poses challenges for care providers, related to appropriate risk assessment, treatment, and surveillance options for at-risk populations. In this presentation, the current CCS Dyslipidemia Guideline Committee will present on the following topics:

(i) In primary prevention, what ancillary approaches can physicians use to counsel individuals toward lifestyle change and identify individuals for earlier treatment? (vascular age, lifetime risk, benefit approach).

(ii) In adults already receiving or intolerant to statins, what is the role of other lipid-modulating drugs compared with placebo reduce CVD events?

(iii) In secondary prevention, what is the most appropriate lipid/lipoprotein threshold for intensification of therapy?

This session will be focused on case-based discussions of these topics and is intended to engage the audience in an informal debate/discussion and inform the guideline committee of the opinions of practitioners across the country.

Target Audience(s):

General: All cardiovascular (clinical and research) health professionals
Clinical cardiologists
General practitioners

Learning Objectives

At the conclusion of this session, participants will be able to:

• identify the benefits of traditional risk models and added value of using vascular age and other approaches for identifying selected patients for earlier dyslipidemia treatment;
• recognize the potential role of other lipid-modulating drugs compared with placebo to reduce CVD events in adults already receiving or intolerant to statins; and
• discuss the evidence for various lipid/lipoprotein thresholds for intensification of therapy, based on recent clinical trials.